Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
Johnson and Johnson
Express Scripts
Colorcon

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 213051

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 213051 describes RYBELSUS, which is a drug marketed by Novo and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the RYBELSUS profile page.

The generic ingredient in RYBELSUS is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.
Summary for 213051
Tradename:RYBELSUS
Applicant:Novo
Ingredient:semaglutide
Patents:5
Formulation / Manufacturing:see details
Pharmacology for NDA: 213051
Suppliers and Packaging for NDA: 213051
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RYBELSUS semaglutide TABLET;ORAL 213051 NDA Novo Nordisk 0169-4303 0169-4303-13 3 BLISTER PACK in 1 CARTON (0169-4303-13) > 10 TABLET in 1 BLISTER PACK (0169-4303-01)
RYBELSUS semaglutide TABLET;ORAL 213051 NDA Novo Nordisk 0169-4303 0169-4303-93 3 BLISTER PACK in 1 CARTON (0169-4303-93) > 10 TABLET in 1 BLISTER PACK (0169-4303-90)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength3MG
Approval Date:Sep 20, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 5, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Sep 20, 2022
Regulatory Exclusivity Use:NEW PRODUCT
Patent:  Start TrialPatent Expiration:Dec 16, 2031Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
Boehringer Ingelheim
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.